ライフサイエンスコーパス: non-carrier

1 gruous and incongruous trials were larger in non carriers.

2 n tumour tissue of G84E variant carriers and non-carriers.

3 e looked on average up to 2 years older than non-carriers.

4 -50.1) more likely to be affected by PD than non-carriers.

5 de earlier in heterozygotes than in mutation non-carriers.

6 ele possibly at decreased risk compared with non-carriers.

7 ptomatic mutation carriers compared to seven non-carriers.

8 n the first-degree relatives of carriers and non-carriers.

9 nd 20% higher triglycerides (P = 0.025) than non-carriers.

10 01; P-value=2.8 x 10(-02)) compared with the non-carriers.

11 uencing verified 13 mutation carriers and 16 non-carriers.

12 at the age of 45 years was 31% versus 75% in non-carriers.

13 12Ala variant allele-carriers compared with non-carriers.

14 e carriers, whereas 10 were determined to be non-carriers.

15 n had higher cortical Abeta-plaque-load than non-carriers.

16 th age, as carriers die earlier in life than non-carriers.

17 gton's disease mutation carriers and 32 were non-carriers.

18 lopian tube in BRCA1/2 mutation carriers and non-carriers.

19 mporal and parietal (18)F-AV1451 uptake than non-carriers.

20 ptoms differed between mutation carriers and non-carriers.

21 exons of PARK2 have greater risk of PD than non-carriers.

22 (40 symptomatic and 78 asymptomatic) and 102 non-carriers.

23 d altered amygdala function as compared with non-carriers.

24 ly symptomatic mutation carriers relative to non-carriers.

25 e at risk of PD that is greater than that of non-carriers.

26 0.028 and 0.08, respectively) as compared to non-carriers.

27 ndent genome-wide signatures than cancers in non-carriers.

28 rriers of the Asp358Ala minor allele than in non-carriers.

29 tion (carriers, mean age=38) whereas 22 were non-carriers.

30 ad higher CB1 receptor binding compared with non-carriers.

31 ecreased in risk carriers when compared with non-carriers.

32 per mmol/L decrease in LDL cholesterol than non-carriers.

33 r, MAF = 0.01%), who weighed 7 kg more than non-carriers.

34 E280A mutation carriers than in age matched non-carriers.

35 ded: 20 PSEN1 E280A mutation carriers and 24 non-carriers.

36 tors for myocardial infarction compared with non-carriers.

37 01; P-value=2.8 x 10(-02)) compared with the non-carriers.

38 tia, asymptomatic carriers, and asymptomatic non-carriers.

39 correctly classifying epsilon4 carriers from non-carriers.

40 sma Abeta(1-42) concentrations (p=0.01) than non-carriers.

41 , GRN, and C9orf72 mutation carriers and 123 non-carriers.

42 have mean adiponectin levels that are 19% of non-carriers.

43 e 1976 to 1986 (P = 0.028) compared with the non-carriers.

44 disease, had higher enzymatic activity than non-carriers (13.69 micromol/l/h versus 11.93 micromol/l

45 (from 76% to 27%) to levels similar to APOE4 non-carriers (27.14%), which strongly indicate protectio

46 est Z score differences between carriers and non-carriers 5 years before expected onset in tests of n

47 nt differences between mutation carriers and non-carriers 5 years before expected onset, when differe

48 ively asymptomatic mutation carriers than in non-carriers (5% versus 17%, P = 0.014) and the odds of

49 lower enzymatic activity than GBA and LRRK2 non-carriers (7.88 micromol/l/h versus 11.93 micromol/l/

50 found to smoke fewer cigarettes per day than non-carriers (AA P = 6.6 x 10(-5), EA P = 0.021).

51 tion of a diaryliodonium salt precursor with non-carrier-added (18)F-fluoride, yielded a product with

52 ld (95% CI=0.74-3.00) for ALS-G, compared to non-carriers after adjusting for SNPs 6 and 9.

53 .52, 1.25-1.85; p=1.74x10(-5)) compared with non-carriers after lobar ICH.

54 ificantly shorter sleep duration compared to non-carriers after the adjustment for individual proport

55 age 58.3 +/- 7.7 years, four females) and 14 non-carriers (age 60.8 +/- 6.9 years, four females), and

56 lood of 34 FTLD expansion carriers, 166 FTLD non-carriers and 103 controls.

57 imaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzh

58 ial and follow-up examinations compared with non-carriers and continued to develop nevi rather than s

59 with individuals with other genotypes (both non-carriers and heterozygous carriers).

60 vi rather than show nevus regression seen in non-carriers and spouse controls.

61 increased in mutation carriers compared with non-carriers and spouse controls.

62 requent in APOE varepsilon4 carriers than in non-carriers and that A(+)N(+) was more, and A(+)N(-) le

63 mpared between genotyped I1307K carriers and non-carriers and their first-degree relatives.

64 ave 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the

65 loci comparing effective allele carriers to non-carriers are 21.48 (95% confidence interval=11.13-41

66 have greater risk of nicotine addiction than non-carriers as assessed by the Fagerstrom Test for Nico

67 tion 2 hours after an oral glucose load than non-carriers (beta = 0.43 mmol l(-1), P = 5.3 x 10(-5)).

68 a42 levels were significantly different from non-carriers but did not differ between preclinical muta

69 Compared with non-carriers, carriers had greater right hippocampal and

70 [homozygotes] vs 75% [heterozygotes] vs 69% [non-carriers]; Cochran-Armitage trend test p=0.0587).

71 r's disease, 18 asymptomatic carriers and 21 non-carrier controls underwent diffusion tensor magnetic

72 tly poorer cumulative survival compared with non-carrier DCM patients: event-free survival at the age

73 was 0.80% in mutation carriers and 0.84% in non-carriers; difference -0.04, SE 0.02) followed by the

74 volume 8.1% in mutation carriers and 8.3% in non-carriers; difference -0.2, SE 0.1).

75 ed psychopathology in mutation carriers over non-carriers during the presymptomatic stage, suggesting

76 ed difference among 50,060 KIF6 carriers and non-carriers enrolled in 8 randomized trials of statin t

77 perception of their current health than did non-carriers, even though they had been told that carrie

78 uantitative measure to compare probands with non-carrier family members rather than a qualitative, di

79 An intermediate nevus phenotype in non-carrier family members suggests the presence of addi

80 ies, including penetrants, non-penetrants or non-carriers for NSCLP.

81 enilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention I

82 The carrier and non-carrier groups did not differ significantly in their

83 Four of the 13 mutation carriers and one non-carrier have developed invasive melanoma.

84 ptomatic carriers) and 30 healthy relatives (non-carrier healthy controls) were assessed with a visua

85 owed significantly higher PIB retention than non-carriers in all brain regions except the hippocampus

86 velop AD have a thinner cerebral cortex than non-carriers in regions known to be affected by typical

87 in clinical benefit among KIF6 carriers and non-carriers in response to therapies that lower LDL cho

88 enefit among KIF6 719Arg allele carriers and non-carriers in response to therapies that reduce LDL ch

89 ilon2 allele had larger ICH volumes than did non-carriers in the discovery phase (p=2.5x10(-5)), in b

90 ite matter between FAD mutation carriers and non-carriers in the preclinical (clinical dementia ratin

91 When compared with non-carriers, LDLR mutation carriers had higher plasma L

92 riers performed significantly less well than non-carriers, matched for age and IQ, on tests of attent

93 3K1-rs889312 were significantly shorter than non-carriers (mean height 162.4 cm [95% CI 162.1-162.7]

94 alasin B inhibited absorption by 92 +/- 7 %; non-carrier-mediated transport is therefore minimal.

95 Compared with non-carriers, mutation carriers were younger at onset an

96 = 0.024) were decreased relative to that of non-carriers (n = 8).

97 ic and symptomatic FAD mutation carriers and non-carrier (NC) relatives.

98 mutation carriers (MCs) and 110 asymptomatic non-carriers (NCs).

99 ptomatic mutation carriers was lower than in non-carriers (odds ratio = 0.50, 95% confidence interval

100 an unfavourable outcome compared with 33% of non-carriers of APOE epsilon4.

101 plaque and tangle load between carriers and non-carriers of BCHE-K still failed to disclose a relati

102 s of apo(a) were higher in the carriers than non-carriers of both rs10455872 and rs3798220.

103 of LPA mRNA were higher in the carriers than non-carriers of rs10455872 (P = 0.0001) and were not dif

104 and were not different between carriers and non-carriers of rs3798220.

105 d not perform significantly more poorly than non-carriers on any of the background tests, on any of t

106 carriers declined slightly more rapidly than non-carriers on most cognitive measures, with processing

107 le with >50 repeats, and was not detected in non-carriers or individuals with an intermediate allele

108 eas no significant decreased was observed in non-carriers (P >0.0125).

109 0.4 versus a mean thinning of 76.8 +/- 22 in non-carriers (p = 0.015).

110 antly higher in FTLD expansion carriers than non-carriers (P = 7.8E-13).

111 cognitive domain in APOE varepsilon4 allele non-carriers (P<0.01).

112 2 Gly2019Ser homozygotes, heterozygotes, and non-carriers (p=0.85).

113 fest neuropsychiatric phenotypes compared to non-carrier parents (P = 0.037, OR = 6).

114 atrophy patterns in C9orf72 carriers versus non-carriers, patient groups showed topographically simi

115 Compared to non-carriers, presymptomatic presenilin 1 mutation carri

116 matic mutation carriers, and 20 asymptomatic non-carriers, ranging in age from 20 to 56 years.

117 women, comparing variant allele carriers to non-carriers, reduced breast cancer risk was associated

118 autoreactive clones compared with those from non-carriers, revealing defective central and peripheral

119 rs are treated or monitored differently from non-carriers, roughly 238 patients would need to be geno

120 Non-carriers showed an intermediate nevus phenotype betw

121 Fibroblasts from ALS8 patients and their non-carrier siblings were successfully reprogrammed to a

122 cognitively normal varepsilon4 carriers and non-carriers simultaneously, (ii) the sensitivity of the

123 ed a model carrier isolate (D30) and a model non-carrier strain (930918-3) to identify differential g

124 age specific differences between carrier and non-carrier strains suggesting a role for mobile genetic

125 level in 20 R221S offspring carriers and 20 non-carriers using two alternative antibodies and determ

126 23.6 +/- 2.2 years; 31 NTRK1-T carriers, 360 non-carriers) using 105-gradient diffusion tensor imagin

127 psilon4 carrier[varepsilon4(+)], varepsilon4 non-carrier[varepsilon4(-)]) and brain-derived neurotrop

128 Compared to non-carriers, we observed nominally significant positive

129 d HRs comparing BMPR2 mutation carriers with non-carriers were 1.42 (95% CI 1.15-1.75; p=0.0011) for

130 ApoE epsilon4 carriers and non-carriers were screened for anosmia, severe hyposmia,

131 ity was reduced in heterozygotes compared to non-carriers when each mutation was compared independent

132 s (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures

133 nt differences between mutation carriers and non-carriers with regard to absolute age, age relative t

134 sease mutation carriers were compared to 106 non-carriers with regard to frequency of behavioural sym

135 f fibrillar Abeta deposition in carriers and non-carriers with regression analysis and to estimate th

136 rior parietal lobule in carriers compared to non-carriers, with trend-level effects in the medial tem